We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Healthcare Payers and GPhA Push for Same Name Biosimilars

Healthcare Payers and GPhA Push for Same Name Biosimilars

July 7, 2014

The FDA would require biosimilars to carry the same name as their reference drug counterparts under a proposal being pushed by healthcare payers and GPhA. The groups hope the proposal will be adopted by FDA in upcoming guidance on biosimilars naming.

A group of 32 pharmacies, health insurers, unions and pension plans, in a July 1 letter to FDA Commissioner Margaret Hamburg, say that multiple names might confuse consumers and make them unnecessarily hesitant to take a biosimilar.

In releasing the letter, GPhA also pointed to another benefit of same name biosimilars raised by the National Council for Prescription Drug Programs: they will head off discrepancies in drug databases and tracking systems that would result from multiple names for the same product.

Major labor unions like the AFL-CIO and AFSCME, as well as insurance and drug providers including American Health Insurance Plans, Walgreens and CVS Caremark signed on to the letter. Pension funds and trusts also signed on, according to GPhA President and CEO Ralph Neas, because they want to reduce healthcare costs for retirees by shifting patients to biosimilars when they are available.

The letter points out that shared names between biosimilars and their reference product are already employed in the EU, Canada, Australia and Japan and have been well accepted.

The naming issue is expected to be the subject of the next draft guidance from the FDA on biosimilars, though the agency hasn’t given any indications yet about what naming scheme it will favor.

Advocates for giving biosimilars different names from their reference products say patients and healthcare providers should know when a biosimilar is being taken so they can assess which drug is the best choice on a case-by-case basis. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing